Rankings
▼
Calendar
BCRX Q4 2025 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
BCRX
BioCryst Pharmaceuticals, Inc.
$2B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$407M
+209.1% YoY
Gross Profit
$397M
97.6% margin
Operating Income
$260M
64.0% margin
Net Income
$246M
60.5% margin
EPS (Diluted)
$1.12
QoQ Revenue Growth
+155.1%
Cash Flow
Operating Cash Flow
$276M
Free Cash Flow
$275M
Stock-Based Comp.
$73M
Balance Sheet
Total Assets
$514M
Total Liabilities
$633M
Stockholders' Equity
-$119M
Cash & Equivalents
$90M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$407M
$132M
+209.1%
Gross Profit
$397M
$125M
+216.3%
Operating Income
$260M
-$5M
+5876.1%
Net Income
$246M
-$27M
+1017.5%
Revenue Segments
License
$708,000
100%
← FY 2025
All Quarters